Back to MTL
(click a #, the slide will appear to the right)
(each is about 50K)
Contents:
[01]
[02]
[03]
[04]
[05]
Biomaterials, some jargon and some very common examples:
[06]
[07]
[08]
A condensed, focused biomaterials history:
[09]
[10]
Costs, quantities and examples of implants:
[11]
[12]
[13]
[14]
Some examples of implant orthopedics:
[15]
[16]
[17]
[18]
Case example 1:
Total elbow failure:
[19]
[20]
[21]
[22]
[23]
[24]
[25]
Case example 2:
Hip implant failure:
[26]
[27]
[28]
[29]
Case example 3:
Hip implant failure:
[30]
[31]
[32]
[33]
Case example 4:
A compilation of 4 failures of hydroxyapatite (HA) coated materials:
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
The FDA and "510k":
[47]
Engineered materials in total hip replacement:
[48]
[49]
Mechanical properties and bioactive properties of biomaterials:
[50]
[51]
Biomaterials R&D through the patent literature:
[52]
53-54
The role of hydroxyapatite coatings:
[53]
[54]
Biological response of hydroxyapatite in the body:
[55]
[56]
[57]
[58]
Interface reactions of hydroxyapatite:
[59]
[60]
Apatite formation of materials:
[61]
[62]
[63]
[64]
Engineered materials and coating techniques:
[65]
[66]
[67]
Thermal spray processing and diagnostic methods:
[68]
[69]
[70]
[71]
[72]
[73]
Thermal spray processing and diagnostic methods:
[74]
[75]
Two specific thermal spray applications:
[76]
Hydroxyapatite standards:
[77]
Phase structure and relationships for hydroxyapatite:
[78]
[79]
[80]
[81]
The importance of the feedstock properties:
[82]
[83]
[84]
Testing of coatings:
[85]
[86]
Model of a cooling hydroxyapatite splat:
[87]
Phase measurement in hydroxyapatite:
[88]
[89]
[90]
Amorphous / crystalline phase control:
[91]
[92]
[93]
[94]
[95]
In vitro degradation:
[96]
[97]
Process / phase relationship model:
[98]
Critical issues and design issues:
[99]
[100]
[101]
[102]
[103]
A summary of biomaterials approaches:
[104]
Summary and conclusions:
[105]
[106]
[107]
[108]
08/06/00
Disclaimer: Don't believe everything that you read.